根据FDA药物监督数据库,探索选择性血红素再吸收抑制剂与狂宫痛风险之间的关联
Yan Wang1, Yajing Lin1, Qing Lin1
1Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.
Scientific reports
|July 28, 2023
概括
选择性血清素再吸收抑制剂 (SSRI) 与更高的拉布多米解症风险有关,这是一个可能致命的疾病. 弗卢沃胺显示出最强的关联,而帕罗克塞丁没有显著的风险.
科学领域:
- 药物监督 药物监督 药物监督
- 临床毒理学 临床毒理学
- 神经科学是一个神经科学.
背景情况:
- 轮骨髓溶解是一种严重的医疗状况,可能导致致命的结果.
- 以前的病例报告表明,选择性血清素再吸收抑制剂 (SSRI) 和狂犬病溶解之间可能存在关联.
研究的目的:
- 调查SSRI的使用与狂犬病发生之间的相关性.
- 通过使用大型不良事件数据库量化与SSRI相关的拉布地质溶解的安全信号.
主要方法:
- 来自美国食品和药物管理局不良事件报告系统 (FAERS) 数据库的报告分析 (2004年1月1日 - 2022年12月31日).
- 使用了四个不成比例分析算法:ROR,PRR,BCPNN和EBGM.
- 对SSRI总体和单个SSRI的检查信号,包括含有fluvoxamine和paroxetine的SSRI,随着和没有同时使用他类药物.
主要成果:
- 检测到与SSRI相关的体胆固化显著阳性信号 (ROR: 2.86).
- 弗卢沃胺表现出最强烈的风险信号,表现出拉布地质溶解的风险信号 (ROR:11.64),而帕洛克塞丁没有显示出显著的信号 (ROR:1.83).
- 即使排除了涉及他类药物的同时使用的病例,SSRI和狂犬病溶解之间的关联仍然很重要.
结论:
- 简单的SSRI与拉布地质溶解的风险增加有关.
- 不同的SSRI之间存在风险信号的显著差异,而流胺具有最高风险.
- 在启动SSRI治疗之前,医疗保健提供者应向患者提供关于rhabdomyolysis潜在风险的建议.
相关概念视频
Pharmacovigilance
891
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
891
Antidepressant Drugs: MAOIs and Other Agents
275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
438
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
438
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
199
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
199
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
311
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
311
Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K


